Total Payments
$13,759
2022 Payments
$1,428
Companies
6
Transactions
32
Payment Breakdown by Category
Consulting$9,300 (67.6%)
Travel$1,843 (13.4%)
Research$1,797 (13.1%)
Food & Beverage$818.27 (5.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,300 | 3 | 67.6% |
| Travel and Lodging | $1,843 | 11 | 13.4% |
| Unspecified | $1,797 | 6 | 13.1% |
| Food and Beverage | $818.27 | 12 | 5.9% |
Payments by Type
General
$11,961
26 transactions
Research
$1,797
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $4,397 | 6 | $0 (2018) |
| Janssen Scientific Affairs, LLC | $3,873 | 7 | $0 (2017) |
| Janssen Products, LP | $2,627 | 3 | $0 (2017) |
| Astellas Pharma Global Development | $1,797 | 6 | $0 (2022) |
| GENZYME CORPORATION | $645.65 | 6 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $419.18 | 4 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $1,428 | 4 | Astellas Pharma Global Development ($1,428) |
| 2021 | $369.83 | 2 | Astellas Pharma Global Development ($369.83) |
| 2019 | $406.15 | 4 | GENZYME CORPORATION ($406.15) |
| 2018 | $4,637 | 8 | Janssen Biotech, Inc. ($4,397) |
| 2017 | $6,919 | 14 | Janssen Scientific Affairs, LLC ($3,873) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/30/2022 | Astellas Pharma Global Development | Xtandi (Drug) | — | In-kind items and services | $255.00 | Research |
| Study: A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) • Category: Oncology | ||||||
| 09/30/2022 | Astellas Pharma Global Development | Xtandi (Drug) | — | In-kind items and services | $469.00 | Research |
| Study: A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) • Category: Oncology | ||||||
| 08/31/2022 | Astellas Pharma Global Development | Xtandi (Drug) | — | In-kind items and services | $469.00 | Research |
| Study: A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) • Category: Oncology | ||||||
| 02/28/2022 | Astellas Pharma Global Development | Xtandi (Drug) | — | In-kind items and services | $234.50 | Research |
| Study: A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) • Category: Oncology | ||||||
| 03/31/2021 | Astellas Pharma Global Development | XTANDI (Drug) | — | In-kind items and services | $234.50 | Research |
| Study: A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) • Category: ONCOLOGY | ||||||
| 03/31/2021 | Astellas Pharma Global Development | XTANDI (Drug) | — | In-kind items and services | $135.33 | Research |
| Study: A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) • Category: ONCOLOGY | ||||||
| 10/24/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $159.79 | General |
| 10/24/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $126.84 | General |
| 10/24/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $100.80 | General |
| 10/24/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $18.72 | General |
| 10/26/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $138.23 | General |
| 10/26/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $101.27 | General |
| 07/13/2018 | Janssen Biotech, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,710.00 | General |
| 07/13/2018 | Janssen Biotech, Inc. | — | Travel and Lodging | In-kind items and services | $572.19 | General |
| 07/13/2018 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 07/13/2018 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 07/13/2018 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 07/13/2018 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $14.90 | General |
| 10/07/2017 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $205.34 | General |
| 10/06/2017 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $71.28 | General |
| 10/05/2017 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $71.28 | General |
| 10/04/2017 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $71.28 | General |
| 08/04/2017 | Janssen Products, LP | — | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| 08/04/2017 | Janssen Products, LP | — | Food and Beverage | In-kind items and services | $117.96 | General |
| 08/04/2017 | Janssen Products, LP | — | Travel and Lodging | Cash or cash equivalent | $8.75 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) | Astellas Pharma Global Development | $1,797 | 6 |
About Scott Tomlins, M.D., PH.D
Scott Tomlins, M.D., PH.D is a Anatomic Pathology healthcare provider based in Ann Arbor, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/25/2009. The National Provider Identifier (NPI) number assigned to this provider is 1164650404.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Scott Tomlins, M.D., PH.D has received a total of $13,759 in payments from pharmaceutical and medical device companies, with $1,428 received in 2022. These payments were reported across 32 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($9,300).
Ad
Practice Information
- Specialty Anatomic Pathology
- Location Ann Arbor, MI
- Active Since 06/25/2009
- Last Updated 04/25/2012
- Taxonomy Code 207ZP0101X
- Entity Type Individual
- NPI Number 1164650404
Products in Payments
- Xtandi (Drug) $1,428
- NO PRODUCT DISCUSSED (Drug) $1,065
- XTANDI (Drug) $369.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Anatomic Pathology Doctors in Ann Arbor
Rouba Ali Fehmi, Md, MD
Anatomic Pathology — Payments: $9,840
Anatomic Pathology $9,840
Gabriel Nunez, Md, MD
Anatomic Pathology — Payments: $8,234
Anatomic Pathology $8,234
Thomas Giordano, Md, MD
Anatomic Pathology — Payments: $2,544
Anatomic Pathology $2,544
Lois Arend, Md, MD
Anatomic Pathology — Payments: $213.14
Anatomic Pathology $213.14
Akriti Gupta, Mbbs, MBBS
Anatomic Pathology — Payments: $172.79
Anatomic Pathology $172.79
Lokman Sung, Md, MD
Anatomic Pathology — Payments: $144.45
Anatomic Pathology $144.45